- Initial Phase 1b results show mean reduction of cerebrospinal fluid mutant huntingtin of 60 to 64% at month 3 with individual reduction of up to 83% and encouraging safety and tolerability with potential for twice yearly dosing -

- Unique targeting approach reduces both mutant huntingtin and shorter mutant HTT1a-

- Placebo-controlled pivotal study planned for 2027, pending regulatory alignment -

- Alnylam to discuss Huntington’s disease program at October 26 RNAi Roundtable -

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.